Dextromethorphan and guaifenesin use must be monitored thoroughly in clients with "very poor metabolizer" CYP2D6 enzyme amounts and sufferers that are sedated. This combination medication provides a massive median poisonous dose (TD50) to median effective dose (ED50) ratio (or therapeutic index) in these clients. Thank you for sharing our content. https://chemicalglobe.com/